P2371

Pamidronate disodium salt hydrate

≥95% (NMR), solid

• Sinónimos: 3-Amino-1-hydroxy-1-phosphonopropanephosphonic acid disodium salt hydrate
• Fórmula empírica (notación de Hill): C₃H₉NO₇P₂Na₂ · xH₂O
• Número de CAS: 57248-88-1
• Peso molecular: 279.03 (anhydrous basis)
• EC Number: 260-647-1
• MDL number: MFCD11045314
• UNSPSC Code: 12352200
• PubChem Substance ID: 24724574
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥95% (NMR)
• form: solid
• color: white
• mp: 300 °C
• solubility: H₂O: 28 mg/mL
• originator: Novartis
• storage temp.: 2-8°C
• SMILES string: O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O
• InChI: 1S/C3H11NO7P2.2Na.H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;1H2/q;2*+1;/p-2
• InChI key: TVQNUQCYOOJTMK-UHFFFAOYSA-L

Descripción

Biochem/physiol Actions

Pamidronate disodium has the ability to block Wnt and β-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth.

Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase (IC₅₀ = 200 nM).

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves